Reuters: Hot Stocks: Safety data on Glaxo COPD drug inconclusive -FDA staff

Reuters: Hot Stocks Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Want new traffic sources? Download a copy of our complimentary eBook today, and read about sources that most marketers are not aware of. From our sponsors

Safety data on Glaxo COPD drug inconclusive -FDA staff Sep 6th 2013, 12:59 Sept 6 | Fri Sep 6, 2013 8:59am EDT Sept 6 (Reuters) - An experimental drug to treat chronic obstructive pulmonary disease made by GlaxoSmithKline Plc and Theravance Inc appears to work, but its safety data are not entirely conclusive, according to medical reviewers for the U.S. Food and Drug Administration. The reviewers posted their opinion on the FDA's website on Friday ahead of a meeting next Tuesday of an outside panel of medical experts, who will discuss the drug and recommend whether the agency should approve it. The FDA is not required to follow the advice of its expert panels but typically does so. The FDA's reviewers said that while the safety database submitted by GSK is fairly large, it is "not entirely conclusive, particularly in regards to cardiovascular safety." The drug, Anoro, is an inhaled combination of vilanterol, a long-acting beta-agonist that is designed to open the airways, and umeclidinium, a long-acting muscarinic receptor antagonist, which works to improve lung function. (Reporting by Toni Clarke in Washington; Editing by Gerald E. McCormick) Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions